Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline

Nicholas J Shaheen, Gary W Falk, Prasad G Iyer, Rhonda F Souza, Rena H Yadlapati, Bryan G Sauer, Sachin Wani, Nicholas J Shaheen, Gary W Falk, Prasad G Iyer, Rhonda F Souza, Rena H Yadlapati, Bryan G Sauer, Sachin Wani

Abstract

Barrett's esophagus (BE) is a common condition associated with chronic gastroesophageal reflux disease. BE is the only known precursor to esophageal adenocarcinoma, a highly lethal cancer with an increasing incidence over the last 5 decades. These revised guidelines implement Grading of Recommendations, Assessment, Development, and Evaluation methodology to propose recommendations for the definition and diagnosis of BE, screening for BE and esophageal adenocarcinoma, surveillance of patients with known BE, and the medical and endoscopic treatment of BE and its associated early neoplasia. Important changes since the previous iteration of this guideline include a broadening of acceptable screening modalities for BE to include nonendoscopic methods, liberalized intervals for surveillance of short-segment BE, and volume criteria for endoscopic therapy centers for BE. We recommend endoscopic eradication therapy for patients with BE and high-grade dysplasia and those with BE and low-grade dysplasia. We propose structured surveillance intervals for patients with dysplastic BE after successful ablation based on the baseline degree of dysplasia. We could not make recommendations regarding chemoprevention or use of biomarkers in routine practice due to insufficient data.

Conflict of interest statement

Potential competing interests: N.J.S. receives research funding from Medtronic, Steris, Pentax, CDx Diagnostics, Interpace Diagnostics, and Lucid Medical; he is a consultant for Cernostics, Phathom Pharmaceuticals, Exact Sciences, Aqua Medical, and Cook Medical. G.W.F. receives research funding from Lucid and Interpace Diagnostics; he is a consultant for Lucid, CDx, Cernostics, Interpace, Exact Sciences, and Phathom Pharmaceuticals. P.G.I. receives research funding from Exact Sciences, Pentax Medical, and Cernostics; he is a consultant to Medtronic, Ambu, Pentax, and Symple Surgical. R.F.S. receives research funding from Sanofi and Phathom Pharmaceuticals; she is a consultant for Cernostics, Phathom Pharmaceuticals, Interpace Diagnostics, Ironwood Pharmaceuticals, ISOThrive, CDx Diagnostics, and AstraZeneca. R.H.Y. receives research funding from Ironwood Pharmaceuticals; she is a consultant for Medtronic, Phathom Pharmaceuticals, Eli Lilly, Ironwood Pharmaceuticals, Diversatek, StatLinkMD, and RJS Mediagnostix. B.G.S. is a consultant for Takeda Pharmaceuticals and Watermark Research Partners. S.W. receives research funding from Lucid Medical, Ambu, and CDx Medical; he is a consultant for Medtronic, Boston Scientific, Interpace Diagnostics, Exact Sciences, and Cernostics.

Copyright © 2022 by The American College of Gastroenterology.

Figures

Figure 1.
Figure 1.
Grading of Barrett’s esophagus using Prague criteria: (a) defining the circumferential extent and (b) maximal extent of the columnar-lined esophagus.
Figure 2.
Figure 2.
Care algorithm for patients noted to have columnar mucosa in the tubular esophagus. Note the stratification of surveillance interval by length of nondysplastic BE. BE, Barrett’s esophagus; EAC, esophageal adenocarcinoma; GEJ, gastroesophageal junction; GI, gastrointestinal; HGD, high-grade dysplasia; LGD, low-grade dysplasia.
Figure 3.
Figure 3.
Nonendoscopic Barrett’s esophagus detection devices. (a) Encapsulated and expanded Cytosponge device. (b and c) Encapsulated and expanded EsophaCap device. (d and e) Retracted and inflated Esocheck device.
Figure 4.
Figure 4.
Algorithm for patients referred for consideration of EET. Please note that these procedures are to be performed using high-definition white light endoscopy and virtual chromoendoscopy and are generally performed after initiation of maximal acid suppressive therapy (twice-daily PPI). Resection of visible lesions should always precede ablative therapy, and this mucosal resection may upstage the BE, in which case the algorithm for the most severe histology should be followed. BE, Barrett’s esophagus; CEIM, complete eradication of intestinal metaplasia; EET, endoscopic eradication therapy; HGD, high-grade dysplasia; LGD, low-grade dysplasia; LVI, lymphovascular invasion; PPI, proton pump inhibitor.
Figure 5.
Figure 5.
Images of band ligation endoscopic mucosal resection. (a) A lesion at the 9 o’clock position, (b) the same lesion, with borders marked with electrocautery, (c) the proximal portion of the lesion banded, and (d) complete resection of the lesion, with the absence of residual cautery markings.
Figure 6.
Figure 6.
Suggested algorithm for post-CEIM surveillance in patients treated endoscopically for dysplastic BE. Panel a demonstrates the patient’s pretreatment long-segment BE, with a maximal extent of 9 cm and a circumferential extent of 7 cm. Panel b demonstrates the posttreatment esophagus, with previous areas of BE demonstrating neosquamous epithelium. Four quadrant biopsies are taken in the high cardia just below the Z line from the top of the gastric folds (blue dots). Four quadrant biopsies are additionally taken from each of the distal 2–3 cm of neosquamous epithelium (green dots). Biopsies taken of normal-appearing tissue above this range, even in previously long-segment disease, have not been demonstrated to have substantial additional yield for dysplasia or buried intestinal metaplasia. BE, Barrett’s esophagus; CEIM, complete eradication of intestinal metaplasia; GEJ, gastroesophageal junction. Adapted with permission from Kahn et al. (219).

References

    1. Barrett NR. Chronic peptic ulcer of the oesophagus and “oesophagitis.” Br J Surg 1950;38:175–82.
    1. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118–24.
    1. Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett’s esophagus. Gastrointest Endosc 2019;90:707–17.
    1. Thrift AP, El-Serag HB, Kanwal F. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol 2021;14(2):122–32.
    1. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline: Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2022;117(1):27–56.
    1. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94.
    1. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–6.
    1. Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol 2013;66:726–35.
    1. Que J, Garman KS, Souza RF, et al. Pathogenesis and cells of origin of Barrett’s esophagus. Gastroenterology 2019;157:349–64.
    1. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett’s esophagus. N Engl J Med 1976;295:476–80.
    1. Clermont M, Falk GW. Clinical guidelines update on the diagnosis and management of Barrett’s esophagus. Dig Dis Sci 2018;63:2122–8.
    1. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: Results from a large population-based study. J Natl Cancer Inst 2011;103:1049–57.
    1. Bandla S, Peters JH, Ruff D, et al. Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells. Ann Surg 2014;260:72–80.
    1. Kelty CJ, Gough MD, Van Wyk Q, et al. Barrett’s oesophagus: Intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol 2007;42: 1271–4.
    1. Gatenby PAC, Ramus JR, Caygill CPJ, et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol 2008;43:524–30.
    1. Liu W, Hahn H, Odze RD, et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol 2009; 104:816–24.
    1. Shaheen NJ, Dulai GS, Ascher B, et al. Effect of a new diagnosis of Barrett’s esophagus on insurance status. Am J Gastroenterol 2005;100: 577–80.
    1. Crockett SD, Lippmann QK, Dellon ES, et al. Health-related quality of life in patients with Barrett’s esophagus: A systematic review. Clin Gastroenterol Hepatol 2009;7:613–23.
    1. Westerhoff M, Hovan L, Lee C, et al. Effects of dropping the requirement for goblet cells from the diagnosis of Barrett’s esophagus. Clin Gastroenterol Hepatol 2012;10:1232–6.
    1. Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett’s esophagus: An observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 2007;102:1154–61.
    1. Sawas T, Killcoyne S, Iyer PG, et al. Identification of prognostic phenotypes of esophageal adenocarcinoma in 2 independent cohorts. Gastroenterology 2018;155:1720–8.
    1. Kerkhof M, Steyerberg EW, Kusters JG, et al. Predicting presence of intestinal metaplasia and dysplasia in columnar-lined esophagus: A multivariate analysis. Endoscopy 2007;39:772–8.
    1. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: The Prague C & M criteria. Gastroenterology 2006;131:1392–9.
    1. Vahabzadeh B, Seetharam AB, Cook MB, et al. Validation of the Prague C & M criteria for the endoscopic grading of Barrett’s esophagus by gastroenterology trainees: A multicenter study. Gastrointest Endosc 2012;75:236–41.
    1. Alvarez Herrero L, Curvers WL, van Vilsteren FG, et al. Validation of the Prague C&M classification of Barrett’s esophagus in clinical practice. Endoscopy 2013;45:876–82.
    1. Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: A population-based study. Am J Gastroenterol 2011;106: 1447–55.
    1. Thota PN, Vennalaganti P, Vennelaganti S, et al. Low risk of high-grade dysplasia or esophageal adenocarcinoma among patients with Barrett’s esophagus less than 1 cm (irregular Z line) within 5 years of index endoscopy. Gastroenterology 2017;152:987–92.
    1. Wani S, Williams JL, Falk GW, et al. An analysis of the GIQuIC Nationwide Quality Registry reveals unnecessary surveillance endoscopies in patients with normal and irregular Z-lines. Am J Gastroenterol 2020;115:1869–78.
    1. Khandwalla HE, Graham DY, Kramer JR, et al. Corrigendum: Barrett’s esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what’s next? Am J Gastroenterol 2014;109:1123.
    1. Jones TF, Sharma P, Daaboul B, et al. Yield of intestinal metaplasia in patients with suspected short-segment Barrett’s esophagus (SSBE) on repeat endoscopy. Dig Dis Sci 2002;47:2108–11.
    1. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in barrett esophagus: A reaffirmation. Hum Pathol 2001;32:368–78.
    1. van der Wel MJ, Coleman HG, Bergman J, et al. Histopathologist features predictive of diagnostic concordance at expert level among a large international sample of pathologists diagnosing Barrett’s dysplasia using digital pathology. Gut 2020;69:811–22.
    1. Duits LC, Phoa KN, Curvers WL, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut 2015;64:700–6.
    1. Duits LC, van der Wel MJ, Cotton CC, et al. Patients with Barrett’s esophagus and confirmed persistent low-grade dysplasia are at increased risk for progression to neoplasia. Gastroenterology 2017;152:993–1001.
    1. Krishnamoorthi R, Lewis JT, Krishna M, et al. Predictors of progression in Barrett’s esophagus with low-grade dysplasia: Results from a multicenter prospective BE registry. Am J Gastroenterol 2017;112: 867–73.
    1. Wani S, Rubenstein JH, Vieth M, et al. Diagnosis and management of low-grade dysplasia in Barrett’s esophagus: Expert review from the Clinical Practice Updates Committee of the American Gastroenterological Association. Gastroenterology 2016;151:822–35.
    1. Codipilly DC, Sawas T, Dhaliwal L, et al. Epidemiology and outcomes of young-onset esophageal adenocarcinoma: An analysis from a population-based database.Cancer Epidemiol Biomarkers Prev 2021;30: 142–9.
    1. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009;360:2277–88.
    1. Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: A randomized clinical trial. JAMA 2014;311:1209–17.
    1. Codipilly DC, Chandar AK, Singh S, et al. The effect of endoscopic surveillance in patients with Barrett’s esophagus: A systematic review and meta-analysis. Gastroenterology 2018;154:2068–86.e5.
    1. Tan MC, Mansour N, White DL, et al. Systematic review with meta-analysis: Prevalence of prior and concurrent Barrett’s oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther 2020; 52:20–36.
    1. Ferrer-Torres D, Nancarrow DJ, Steinberg H, et al. Constitutively higher level of GSTT2 in esophageal tissues from African Americans protects cells against DNA damage. Gastroenterology 2019;156:1404–15.
    1. Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett’s esophagus: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:1046–55.
    1. Rubenstein JH, Scheiman JM, Sadeghi S, et al. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: Synthesis and estimates from population studies. Am J Gastroenterol 2011;106:254–60.
    1. Moriarty JP, Shah ND, Rubenstein JH, et al. Costs associated with Barrett’s esophagus screening in the community: An economic analysis of a prospective randomized controlled trial of sedated versus hospital unsedated versus mobile community unsedated endoscopy. Gastrointest Endosc 2018;87:88–94.
    1. Kamboj AK, Katzka DA, Iyer PG. Endoscopic screening for Barrett’s esophagus and esophageal adenocarcinoma: Rationale, candidates, and challenges. Gastrointest Endosc Clin N Am 2021;31:27–41.
    1. Kramer JR, Shakhatreh MH, Naik AD, et al. Use and yield of endoscopy in patients with uncomplicated gastroesophageal reflux disorder. JAMA Intern Med 2014;174:462–5.
    1. Barbiere JM, Lyratzopoulos G. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett’s esophagus: A review. Gastroenterology 2009;137:1869–76.
    1. Gerson LB, Groeneveld PW, Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2004;2: 868–79.
    1. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: A cost-utility analysis. Ann Intern Med 2003;138:176–86.
    1. Sami SS, Dunagan KT, Johnson ML, et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett’s esophagus screening in the community. Am J Gastroenterol 2015;110:148–58.
    1. Eloubeidi MA, Provenzale D. Does this patient have Barrett’s esophagus? The utility of predicting Barrett’s esophagus at the index endoscopy. Am J Gastroenterol 1999;94:937–43.
    1. Rubenstein JH, Morgenstern H, Appelman H, et al. Prediction of Barrett’s esophagus among men. Am J Gastroenterol 2013;108:353–62.
    1. Thrift AP, Garcia JM, El-Serag HB. A multibiomarker risk score helps predict risk for Barrett’s esophagus. Clin Gastroenterol Hepatol 2014;12: 1267–71.
    1. Rubenstein JH, McConnell D, Waljee AK, et al. Validation and comparison of tools for selecting individuals to screen for Barrett’s esophagus and early neoplasia. Gastroenterology 2020;158:2082–92.
    1. Shariff MK, Bird-Lieberman EL, O’Donovan M, et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett’s esophagus. Gastrointest Endosc 2012;75:954–61.
    1. Chang JY, Talley NJ, Locke GR III, et al. Population screening for barrett esophagus: A prospective randomized pilot study. Mayo Clin Proc 2011; 86:1174–80.
    1. Peery AF, Hoppo T, Garman KS, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy. Gastrointest Endosc 2012;75:945–53.
    1. Honing J, Kievit W, Bookelaar J, et al. Endosheath ultrathin transnasal endoscopy is a cost-effective method for screening for Barrett’s esophagus in patients with GERD symptoms. Gastrointest Endosc 2019; 89:712–22.
    1. Alashkar B, Faulx AL, Hepner A, et al. Development of a program to train physician extenders to perform transnasal esophagoscopy and screen for Barrett’s esophagus. Clin Gastroenterol Hepatol 2014;12: 785–92.
    1. Vaughan TL, Fitzgerald RC. Precision prevention of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2015;12:243–8.
    1. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670–7.
    1. Ward EM, Wolfsen HC, Achem SR, et al. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006;101:12–7.
    1. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology 2002;123: 461–7.
    1. Nguyen TH, Thrift AP, Rugge M, et al. Prevalence of Barrett’s esophagus and performance of societal screening guidelines in an unreferred primary care population of U.S. veterans. Gastrointest Endosc 2021;93: 409–19.
    1. Januszewicz W, Tan WK, Lehovsky K, et al. Safety and acceptability of esophageal cytosponge cell collection device in a pooled analysis of data from individual patients. Clin Gastroenterol Hepatol 2019;17:647–56.
    1. Fitzgerald RC, di Pietro M, O’Donovan M, et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: A multicentre, pragmatic, randomised controlled trial. Lancet 2020;396:333–44.
    1. Benaglia T, Sharples LD, Fitzgerald RC, et al. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology 2013;144:62–73.
    1. Peters Y, Schrauwen RWM, Tan AC, et al. Detection of Barrett’s oesophagus through exhaled breath using an electronic nose device. Gut 2020;69:1169–72.
    1. Rodriguez S, Mattek N, Lieberman D, et al. Barrett’s esophagus on repeat endoscopy: Should we look more than once? Am J Gastroenterol 2008; 103:1892–7.
    1. Suna N, Parlak E, Kuzu UB, et al. The prevalence of Barrett esophagus diagnosed in the second endoscopy: A retrospective, observational study at a tertiary center. Medicine (Baltimore) 2016;95:e3313.
    1. Malfertheiner P, Nocon M, Vieth M, et al. Evolution of gastroesophageal reflux disease over 5 years under routine medical care—The ProGERD study. Aliment Pharmacol Ther 2012;35:154–64.
    1. Hanna S, Rastogi A, Weston AP, et al. Detection of Barrett’s esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 2006;101:1416–20.
    1. Modiano N, Gerson LB. Risk factors for the detection of Barrett’s esophagus in patients with erosive esophagitis. Gastrointest Endosc 2009;69:1014–20.
    1. Gupta N, Gaddam S, Wani SB, et al. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc 2012;76:531–8.
    1. Coletta M, Sami SS, Nachiappan A, et al. Acetic acid chromoendoscopy for the diagnosis of early neoplasia and specialized intestinal metaplasia in Barrett’s esophagus: A meta-analysis. Gastrointest Endosc 2016;83:57–67.
    1. Sharma P, Hawes RH, Bansal A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: A prospective, international, randomised controlled trial. Gut 2013;62:15–21.
    1. Sharma P, Bergman JJ, Goda K, et al. Development and validation of a classification system to identify high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus using narrow-band imaging. Gastroenterology 2016;150:591–8.
    1. Committee AT, Thosani N, Abu Dayyeh BK, et al. ASGE Technology Committee systematic review and meta-analysis assessing the ASGE Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for adopting real-time imaging-assisted endoscopic targeted biopsy during endoscopic surveillance of Barrett’s esophagus. Gastrointest Endosc 2016;83:684–98.
    1. de Groof AJ, Fockens KN, Struyvenberg MR, et al. Blue-light imaging and linked-color imaging improve visualization of Barrett’s neoplasia by nonexpert endoscopists. Gastrointest Endosc 2020;91:1050–7.
    1. Everson MA, Lovat LB, Graham DG, et al. Virtual chromoendoscopy by using optical enhancement improves the detection of Barrett’s esophagus-associated neoplasia. Gastrointest Endosc 2019;89:247–56.
    1. Xiong YQ, Ma SJ, Zhou JH, et al. A meta-analysis of confocal laser endomicroscopy for the detection of neoplasia in patients with Barrett’s esophagus. J Gastroenterol Hepatol 2016;31:1102–10.
    1. Sharma P, Meining AR, Coron E, et al. Real-time increased detection of neoplastic tissue in Barrett’s esophagus with probe-based confocal laser endomicroscopy: Final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc 2011;74: 465–72.
    1. Houston T, Sharma P. Volumetric laser endomicroscopy in Barrett’s esophagus: Ready for primetime. Transl Gastroenterol Hepatol 2020;5: 27.
    1. Struyvenberg M, Kahn A, Fleischer D, et al. Expert assessment on volumetric laser endomicroscopy full scans in Barrett’s esophagus patients with or without high grade dysplasia or early cancer. Endoscopy 2021;53:218–25.
    1. de Groof AJ, Struyvenberg MR, van der Putten J, et al. Deep-learning system detects neoplasia in patients with Barrett’s esophagus with higher accuracy than endoscopists in a multistep training and validation study with benchmarking. Gastroenterology 2020;158:915–29.
    1. de Groof AJ, Struyvenberg MR, Fockens KN, et al. Deep learning algorithm detection of Barrett’s neoplasia with high accuracy during live endoscopic procedures: A pilot study (with video). Gastrointest Endosc 2020;91:1242–50.
    1. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus [see comments]. Gastroenterology 1993;105:40–50.
    1. Fitzgerald RC, Saeed IT, Khoo D, et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett’s esophagus. Dig Dis Sci 2001;46:1892–8.
    1. Abela JE, Going JJ, Mackenzie JF, et al. Systematic four-quadrant biopsy detects Barrett’s dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol 2008;103:850–5.
    1. Nachiappan A, Ragunath K, Card T, et al. Diagnosing dysplasia in Barrett’s oesophagus still requires Seattle protocol biopsy in the era of modern video endoscopy: Results from a tertiary centre Barrett’s dysplasia database. Scand J Gastroenterol 2020;55:9–13.
    1. Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009;7:736–42.
    1. Wani S, Williams JL, Komanduri S, et al. Endoscopists systematically undersample patients with long-segment Barrett’s esophagus: An analysis of biopsy sampling practices from a quality improvement registry. Gastrointest Endosc 2019;90:732–41.
    1. Roumans CAM, van der Bogt RD, Steyerberg EW, et al. Adherence to recommendations of Barrett’s esophagus surveillance guidelines: A systematic review and meta-analysis. Endoscopy 2020;52:17–28.
    1. Old O, Moayyedi P, Love S, et al. Barrett’s Oesophagus Surveillance versus endoscopy at need Study (BOSS): Protocol and analysis plan for a multicentre randomized controlled trial. J Med Screen 2015;22:158–64.
    1. Corley DA, Mehtani K, Quesenberry C, et al. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinoma. Gastroenterology 2013;145:312–9.
    1. Krishnamoorthi R, Mohan BP, Jayaraj M, et al. Risk of progression in Barrett’s esophagus indefinite for dysplasia: A systematic review and meta-analysis. Gastrointest Endosc 2020;91:3–10.
    1. Frei NF, Stachler MD, Bergman J. Risk stratification in Barrett’s esophagus patients with diagnoses of indefinite for dysplasia: The definite silver bullet has not (yet) been found. Gastrointest Endosc 2020;91:11–3.
    1. Henn AJ, Song KY, Gravely AA, et al. Persistent indefinite for dysplasia in Barrett’s esophagus is a risk factor for dysplastic progression to low-grade dysplasia. Dis Esophagus 2020;33:doaa015.
    1. Whiteman DC, Appleyard M, Bahin FF, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett’s esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol 2015;30:804–20.
    1. Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy 2017;49:191–8.
    1. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014;63:7–42.
    1. Hamade N, Vennelaganti S, Parasa S, et al. Lower annual rate of progression of short-segment vs long-segment Barrett’s esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2019;17:864–8.
    1. Chandrasekar VT, Hamade N, Desai M, et al. Significantly lower annual rates of neoplastic progression in short- compared to long-segment nondysplastic Barrett’s esophagus: A systematic review and meta-analysis. Endoscopy 2019;51:665–72.
    1. Parasa S, Vennalaganti S, Gaddam S, et al. Development and validation of a model to determine risk of progression of Barrett’s esophagus to neoplasia. Gastroenterology 2018;154:1282–9.e2.
    1. Kunzmann AT, Thrift AP, Johnston BT, et al. External validation of a model to determine risk of progression of Barrett’s oesophagus to neoplasia. Aliment Pharmacol Ther 2019;49:1274–81.
    1. Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc 2019;90: 335–59.
    1. Suresh Kumar VC, Harne P, Patthipati VS, et al. Wide-area transepithelial sampling in adjunct to forceps biopsy increases the absolute detection rates of Barrett’s oesophagus and oesophageal dysplasia: A meta-analysis and systematic review. BMJ Open Gastroenterol 2020;7:e000494.
    1. Singer ME, Smith MS. Wide area transepithelial sampling with computer-assisted analysis (WATS(3D)) is cost-effective in Barrett’s esophagus screening. Dig Dis Sci 2021;66(5):1572–9.
    1. Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: Diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016;111: 30–50; quiz 51.
    1. Snyder P, Dunbar KB, Cipher DJ, et al. Aberrant p53 immostaining in Barrett’s esophagus predicts neoplastic progression: Systematic review and meta-analyses. Dig Dis Sci 2019;64(5):1089–97.
    1. Altaf K, Xiong JJ, la Iglesia D, et al. Meta-analysis of biomarkers predicting risk of malignant progression in Barrett’s oesophagus. Br J Surg 2017;104:493–502.
    1. Janmaat VT, van Olphen SH, Biermann KE, et al. Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett’s oesophagus surveillance: A systematic review and meta-analysis. PLoS One 2017;12:e0186305.
    1. Prichard JW, Davison JM, Campbell BB, et al. TissueCypher: A systems biology approach to anatomic pathology. J Pathol Inform 2015;6:48.
    1. Critchley-Thorne RJ, Duits LC, Prichard JW, et al. A tissue systems pathology assay for high-risk Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 2016;25:958–68.
    1. Critchley-Thorne RJ, Davison JM, Prichard JW, et al. A tissue systems pathology test detects abnormalities associated with prevalent high-grade dysplasia and esophageal cancer in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 2017;26:240–8.
    1. Davison JM, Goldblum J, Grewal US, et al. Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett’s esophagus. Am J Gastroenterol 2020;115:843–52.
    1. Frei NF, Konte K, Bossart EA, et al. Independent validation of a tissue systems pathology assay to predict future progression in nondysplastic Barrett’s esophagus: A spatial-temporal analysis. Clin Transl Gastroenterol 2020;11:e00244.
    1. Frei NF, Khoshiwal AM, Konte K, et al. Tissue systems pathology test objectively risk stratifies Barrett’s esophagus patients with low-grade dysplasia. Am J Gastroenterol 2021;116(4):675–82.
    1. Hao J, Critchley-Thorne R, Diehl DL, et al. A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus. Clinicoecon Outcomes Res 2019;11:623–35.
    1. Prasad GA, Bansal A, Sharma P, et al. Predictors of progression in Barrett’s esophagus: Current knowledge and future directions. Am J Gastroenterol 2010;105:1490–502.
    1. Rubenstein JH, Vakil N, Inadomi JM. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2005;22:135–46.
    1. Srivastava A, Appelman H, Goldsmith JD, et al. The use of ancillary stains in the diagnosis of barrett esophagus and Barrett esophagus associated dysplasia: Recommendations from the Rodger C. Haggitt Gastrointestinal Pathology Society. Am J Surg Pathol 2017;41:e8–21.
    1. Rubenstein JH, Noureldin M, Tavakkoli A, et al. Utilization of surveillance endoscopy for Barrett’s esophagus in Medicare enrollees. Gastroenterology 2020;158:773–5.
    1. Omidvari AH, Hazelton WD, Lauren BN, et al. The optimal age to stop endoscopic surveillance of Barrett’s esophagus patients based on sex and comorbidity: A comparative cost-effectiveness analysis. Gastroenterology 2021;161(2):487–94.
    1. Park WG, Shaheen NJ, Cohen J, et al. Quality indicators for EGD. Am J Gastroenterol 2015;110:60–71.
    1. Sharma P, Katzka DA, Gupta N, et al. Quality indicators for the management of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma: International consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology 2015;149:1599–606.
    1. Sharma P, Parasa S, Shaheen N. Developing quality metrics for upper endoscopy. Gastroenterology 2020;158:9–13.
    1. Wani S, Williams JL, Komanduri S, et al. Over-utilization of repeat upper endoscopy in patients with non-dysplastic Barrett’s esophagus: A quality registry study. Am J Gastroenterol 2019;114:1256–64.
    1. Wani S, Williams JL, Komanduri S, et al. Time trends in adherence to surveillance intervals and biopsy protocol among patients with Barrett’s esophagus. Gastroenterology 2020;158:770–2.
    1. Wani S, Gyawali CP, Katzka DA. AGA clinical practice update on reducing rates of post-endoscopy esophageal adenocarcinoma: Commentary. Gastroenterology 2020;159:1533–7.
    1. Vajravelu RK, Kolb JM, Thanawala SU, et al. Characterization of prevalent, post-endoscopy, and incident esophageal cancer in the United States: A large retrospective cohort study. Clin Gastroenterol Hepatol 2021. (doi: 10.1016/j.cgh.2021.02.005).
    1. Sawas T, Majzoub AM, Haddad J, et al. Magnitude and time-trend analysis of post-endoscopy esophageal adenocarcinoma: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022;20:e31–50.
    1. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825–31.
    1. Cook MB, Corley DA, Murray LJ, et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: A pooled analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). PLoS One 2014;9:e103508.
    1. Moayyedi P, Armstrong D, Hunt RH, et al. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS—A cluster-randomized trial. Am J Gastroenterol 2010;105:2341–6.
    1. Falk GW, Buttar NS, Foster NR, et al. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett’s esophagus. Gastroenterology 2012;143:917–26.
    1. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology 1999;117:327–35.
    1. Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: A systematic review and meta-analysis. Gut 2014;63:1229–37.
    1. Hu Q, Sun TT, Hong J, et al. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: A systematic review and meta-analysis. PLoS One 2017;12:e0169691.
    1. Spechler SJ, Sharma P, Traxler B, et al. Gastric and esophageal pH in patients with Barrett’s esophagus treated with three esomeprazole dosages: A randomized, double-blind, crossover trial. Am J Gastroenterol 2006;101:1964–71.
    1. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett’s esophagus. Am J Gastroenterol 1994;89:989–91.
    1. Wani S, Sampliner RE, Weston AP, et al. Lack of predictors of normalization of oesophageal acid exposure in Barrett’s oesophagus. Aliment Pharmacol Ther 2005;22:627–33.
    1. Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): A randomised factorial trial. Lancet 2018;392:400–8.
    1. Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 2017;153:35–48.
    1. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2019;157: 682–91.
    1. Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: Data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther 2015;41:1162–74.
    1. Buas MF, He Q, Johnson LG, et al. Germline variation in inflammation-related pathways and risk of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut 2017;66:1739–47.
    1. Hashemi Goradel N, Najafi M, Salehi E, et al. Cyclooxygenase-2 in cancer: A review. J Cell Physiol 2019;234:5683–99.
    1. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 2003;124:47–56.
    1. Gammon MD, Terry MB, Arber N, et al. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: A population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:34–9.
    1. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 2011;377:31–41.
    1. Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012; 142:442–52.
    1. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical anti-reflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol 2003;98(11): 2390–4.
    1. Maret-Ouda J, Konings P, Lagergren J, et al. Antireflux surgery and risk of esophageal adenocarcinoma: A systematic review and meta-analysis. Ann Surg 2016;263:251–7.
    1. Chang EY, Morris CD, Seltman AK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: A systematic review. Ann Surg 2007;246:11–21.
    1. Parrilla P, Martinez de Haro LF, Ortiz A, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg 2003;237:291–8.
    1. Standards of Practice Committee, Wani S, Qumseya B, et al. Endoscopic eradication therapy for patients with Barrett’s esophagus-associated dysplasia and intramucosal cancer. Gastrointest Endosc 2018;87:907–31.
    1. Dunbar KB, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett’s esophagus: A systematic review. Am J Gastroenterol 2012;107:850–62.
    1. Qumseya BJ, Wani S, Desai M, et al. Adverse events after radiofrequency ablation in patients with Barrett’s esophagus: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:1086–95.
    1. Wu J, Pan YM, Wang TT, et al. Endotherapy versus surgery for early neoplasia in Barrett’s esophagus: A meta-analysis. Gastrointest Endosc 2014;79:233–41.
    1. Han S, Kolb JM, Hosokawa P, et al. The volume-outcome effect calls for centralization of care in esophageal adenocarcinoma: Results from a large national cancer registry. Am J Gastroenterol 2020;116(4):811–5.
    1. Wani S, Muthusamy VR, Shaheen NJ, et al. Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: The TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium. Gastrointest Endosc 2017;86(1):1–17.
    1. Wani S, Sharma P. Challenges with endoscopic therapy for Barrett’s esophagus. Gastroenterol Clin North Am 2015;44:355–72.
    1. Wolf WA, Pasricha S, Cotton C, et al. Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrett’s esophagus. Gastroenterology 2015;149:1752–61.
    1. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008;57:1200–6.
    1. Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s esophagus: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:1245–55.
    1. Phoa KN, Pouw RE, van Vilsteren FG, et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: A Netherlands cohort study. Gastroenterology 2013;145:96–104.
    1. Pasricha S, Bulsiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for Barrett’s esophagus. Clin Gastroenterol Hepatol 2014;12:1840–7.
    1. Komanduri S, Kahrilas PJ, Krishnan K, et al. Recurrence of Barrett’s esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol 2017;112:556–66.
    1. Fujii-Lau LL, Cinnor B, Shaheen N, et al. Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett’s esophagus: A systematic review and meta-analysis. Endosc Int Open 2017;5:E430–49.
    1. Krishnamoorthi R, Singh S, Ragunathan K, et al. Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy. Gastrointest Endosc 2016;83:1090–106.
    1. Wani S, Han S, Kushnir V, et al. Recurrence is rare following complete eradication of intestinal metaplasia in patients with Barrett’s esophagus and peaks at 18 months. Clin Gastroenterol Hepatol 2020;18:2609–17.
    1. Sami SS, Ravindran A, Kahn A, et al. Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: An international multicentre study. Gut 2019;68:1379–85.
    1. Badreddine RJ, Prasad GA, Lewis JT, et al. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol 2010;8:248–53.
    1. Manner H, Pech O, Heldmann Y, et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol2013; 11:630–5.
    1. Scholvinck D, Kunzli H, Meijer S, et al. Management of patients with T1b esophageal adenocarcinoma: A retrospective cohort study on patient management and risk of metastatic disease. Surg Endosc 2016;30: 4102–13.
    1. Otaki F, Ma GK, Krigel A, et al. Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: A multicenter cohort study. Gastrointest Endosc 2020;92:31–9.
    1. Manner H, Pech O, Heldmann Y, et al. The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. Surg Endosc 2015;29:1888–96.
    1. Singh S, Manickam P, Amin AV, et al. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: A systematic review and meta-analysis. Gastrointest Endosc 2014;79: 897–909.e4; quiz 983.e1, 983.e3.
    1. Rubenstein JH, Waljee AK, Dwamena B, et al. Yield of higher-grade neoplasia in Barrett’s esophagus with low-grade dysplasia is double in the first year following diagnosis. Clin Gastroenterol Hepatol 2018;16: 1529–30.
    1. O’Byrne LM, Witherspoon J, Verhage RJJ, et al. Barrett’s Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett’s esophagus: Report of the RIBBON network. Dis Esophagus 2020;33: doaa009.
    1. Kestens C, Offerhaus GJ, van Baal JW, et al. Patients with Barrett’s esophagus and persistent low-grade dysplasia have an increased risk for high-grade dysplasia and cancer. Clin Gastroenterol Hepatol 2016;14: 956–62.
    1. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology 2011;141:460–8.
    1. Omidvari AH, Ali A, Hazelton WD, et al. Optimizing management of patients with Barrett’s esophagus and low-grade or No dysplasia based on comparative modeling. Clin Gastroenterol Hepatol 2020;18:1961–9.
    1. Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology 2012; 143:567–75.
    1. Vennalaganti P, Kanakadandi V, Goldblum JR, et al. Discordance among pathologists in the United States and Europe in diagnosis of low-grade dysplasia for patients with Barrett’s esophagus. Gastroenterology 2017;152:564–70.
    1. American Gastroenterological A, Spechler SJ, Sharma P, et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011;140: 1084–91.
    1. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383–7.
    1. Downs-Kelly E, Mendelin JE, Bennett AE, et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett’s esophagus biopsies. Am J Gastroenterol 2008;103:2333–40.
    1. Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology 2011; 141:1179–86, 1186.
    1. Mino-Kenudson M, Hull MJ, Brown I, et al. EMR for Barrett’s esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc 2007;66: 660–6.
    1. Podboy A, Kolahi KS, Friedland S, et al. Endoscopic submucosal dissection is associated with less pathologic uncertainty than endoscopic mucosal resection in diagnosing and staging Barrett’s-related neoplasia. Dig Endosc 2020;32:346–54.
    1. Wani S, Mathur SC, Curvers WL, et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett’s dysplasia. Clin Gastroenterol Hepatol 2010;8:783–8.
    1. Wani S, Abrams J, Edmundowicz SA, et al. Endoscopic mucosal resection results in change of histologic diagnosis in Barrett’s esophagus patients with visible and flat neoplasia: A multicenter cohort study. Dig Dis Sci 2013;58:1703–9.
    1. Peters FP, Brakenhoff KP, Curvers WL, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett’s esophagus. Gastrointest Endosc 2008;67:604–9.
    1. Choi J, Chung H, Lee A, et al. Role of endoscopic ultrasound in selecting superficial esophageal cancers for endoscopic resection. Ann Thorac Surg 2021;111(5):1689–95.
    1. Bartel MJ, Wallace TM, Gomez-Esquivel RD, et al. Role of EUS in patients with suspected Barrett’s esophagus with high-grade dysplasia or early esophageal adenocarcinoma: Impact on endoscopic therapy. Gastrointest Endosc 2017;86:292–8.
    1. Prasad GA, Buttar NS, Wongkeesong LM, et al. Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett’s esophagus. Am J Gastroenterol 2007;102:2380–6.
    1. Leggett CL, Lewis JT, Wu TT, et al. Clinical and histologic determinants of mortality for patients with Barrett’s esophagus-related T1 esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2015;13:658–64.
    1. Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014;146:652–60.
    1. Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology 2009;137(3):815–23.
    1. The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003;58:S3–43.
    1. Endoscopic Classification Review Group. Update on the Paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy 2005;37:570–8.
    1. Yang D, Zou F, Xiong S, et al. Endoscopic submucosal dissection for early Barrett’s neoplasia: A meta-analysis. Gastrointest Endosc 2018;87: 1383–93.
    1. Codipilly DC, Dhaliwal L, Oberoi M, et al. Comparative outcomes of cap assisted endoscopic resection and endoscopic submucosal dissection in dysplastic Barrett’s esophagus. Clin Gastroenterol Hepatol 2022;20: 65–73.e1.
    1. Manner H, Rabenstein T, Pech O, et al. Ablation of residual Barrett’s epithelium after endoscopic resection: A randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). Endoscopy 2014;46:6–12.
    1. van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: A multicentre randomised trial. Gut 2011;60:765–73.
    1. Ghorbani S, Tsai FC, Greenwald BD, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s dysplasia: Results of the National Cryospray Registry. Dis Esophagus 2016;29:241–7.
    1. Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc 2010;71:680–5.
    1. Visrodia K, Zakko L, Singh S, et al. Cryotherapy for persistent Barrett’s esophagus after radiofrequency ablation: A systematic review and meta-analysis. Gastrointest Endosc 2018;87:1396–404.e1.
    1. Canto MI, Trindade AJ, Abrams J, et al. Multifocal cryoballoon ablation for eradication of Barrett’s esophagus-related neoplasia: A prospective multicenter clinical trial. Am J Gastroenterol 2020;115:1879–90.
    1. Agarwal S, Alshelleh M, Scott J, et al. Comparative outcomes of radiofrequency ablation and cryoballoon ablation in dysplastic Barrett’s esophagus: A propensity score-matched cohort study. Gastrointest Endosc 2022;95(3):422–431.
    1. Pasricha S, Cotton C, Hathorn KE, et al. Effects of the learning curve on efficacy of radiofrequency ablation for Barrett’s esophagus. Gastroenterology 2015;149:890–6.
    1. Fudman DI, Lightdale CJ, Poneros JM, et al. Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett’s esophagus. Gastrointest Endosc 2014;80:71–7.
    1. Tan MC, Kanthasamy KA, Yeh AG, et al. Factors associated with recurrence of Barrett’s esophagus after radiofrequency ablation. Clin Gastroenterol Hepatol 2019;17:65–72.
    1. Markar SR, Mackenzie H, Ni M, et al. The influence of procedural volume and proficiency gain on mortality from upper GI endoscopic mucosal resection. Gut 2018;67:79–85.
    1. Kolb JM, Davis C, Wani S. Durability of endoscopic eradication therapy for Barrett’s esophagus-related neoplasia: A call for centralized care. Gastroenterology 2022;162:343–5.
    1. Kahn A, Shaheen NJ, Iyer PG. Approach to the post-ablation Barrett’s esophagus patient. Am J Gastroenterol 2020;115:823–31.
    1. Sawas T, Iyer PG, Alsawas M, et al. Higher rate of Barrett’s detection in the first year after successful endoscopic therapy: Meta-analysis. Am J Gastroenterol 2018;113:959–71.
    1. Omar M, Thaker AM, Wani S, et al. Anatomic location of Barrett’s esophagus recurrence after endoscopic eradication therapy: Development of a simplified surveillance biopsy strategy. Gastrointest Endosc 2019;90:395–403.
    1. Cotton CC, Wolf WA, Pasricha S, et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus: Endoscopic findings and anatomic location. Gastrointest Endosc 2015;81:1362–9.
    1. Cotton CC, Haidry R, Thrift AP, et al. Development of evidence-based surveillance intervals after radiofrequency ablation of Barrett’s esophagus. Gastroenterology 2018;155:316–26.
    1. Solfisburg QS, Sami SS, Gabre J, et al. Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrett’s esophagus. Gastrointest Endosc 2021;93(6): 1250–7.
    1. Wani S, Muthusamy VR, Shaheen NJ, et al. Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium. Am J Gastroenterol 2017;112:1032–48.
    1. Ross-Innes CS, Debiram-Beecham I, O’Donovan M, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: A multicenter case-control study. PLoS Med 2015;12:e1001780.
    1. Shaheen NJ, Komanduri S, Muthusamy VR, et al. Acceptability and adequacy of a non-endoscopic cell collection device for diagnosis of Barrett’s esophagus: Lessons learned. Dig Dis Sci 2022;67:177–86.
    1. Iyer PG, Taylor WR, Johnson ML, et al. Accurate nonendoscopic detection of Barrett’s esophagus by methylated DNA markers: A multisite case control study. Am J Gastroenterol 2020;115:1201–9.
    1. Iyer PG, Taylor WR, Slettedahl SW, et al. Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett’s esophagus in a multi-site case-control study. Gastrointest Endosc 2021; 94(3):498–505.
    1. Moinova HR, LaFramboise T, Lutterbaugh JD, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus. Sci Transl Med 2018;10:eaao5848.
    1. Wang Z, Kambhampati S, Cheng Y, et al. Methylation biomarker panel performance in EsophaCap cytology samples for diagnosing Barrett’s esophagus: A prospective validation study. Clin Cancer Res 2019;25: 2127–35.
    1. Kolb JM, Wani S. Endoscopic eradication therapy for Barrett’s oesophagus: State of the art. Curr Opin Gastroenterol 2020;36:351–8.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する